Global
Leuprolide Acetate Market - Overview
Leuprolide
acetate is a synthetic nonapeptide analog of naturally occurring
gonadotropin-releasing hormone names as Lupron. There are various uses of
Lupron include the treatment of endometriosis, breast cancer and prostate
cancer. It is one of the on important medicines and is the WHO Model List of,
essential medical required in a fundamental well-being system.
The
global Leuprolide Acetate market is expected to grow at a steady growth during
the forecast period 2017-2023. The major factor increasing the growth of the
market include increasing prevalence of Prostate cancer among individuals
especially with aged individuals. Moreover, breast cancer has been a key market
driver for the leuprolide market globally. Increasing use of leuprolide for the
purpose of endometriosis treatment has fuelled the growth of the market.
Between the ages of 15 and 44 women, endometriosis is affected to one or more
in ten women in the United States, leading to pelvic discomfort and
infertility, production loss and poor quality of life. The demand for
leuprolide in veterinary treatment is another factor which adds to the growth
of leuprolide acetate market.
The
market is forecasted to demonstrate a steady growth by 2023, surpassing its
previous growth records in terms of value with a striking CAGR during the
anticipated period 2017–2023.
Global
Leuprolide Acetate Market - Competitive Analysis
Characterized
by the presence of several well-established and small players, the global
market of leuprolide acetate appears to be highly competitive and fragmented.
With well-established market in the North America and European region with
major companies having their home in the regions and generating maximum market
share. These companies have expanded their operating unit in various other
emerging regions as well. Moreover the other small and medium scale players are
generating revenue from local market.
With
top selling cancer products, Takeda and AbbVie account for the major market
share for the leuprolide acetate market across the globe. Although there are
various other companies involved in the development of the product.
Myovant Sciences a Switzerland based company involved in the
development of new drug that may be able to cure both women’s health disorders
and prostate cancer. Myovant with its new product relugolix has a diverse
mechanism of action that that of AbbVie's Lupron Depot, letting it work faster,
while the therapy is presently in last-stage of its development, with data
predicted in 2019.
Global
Leuprolide Acetate Market - Regional Analysis
The
global market is segmented into the various regions including North America,
Europe, Asia Pacific, and the Middle East & Africa.
North
America accounted for the largest market share. The major factor influencing
the growth of the market include increasing aging population that is key factor
which will drive the demand for leuprolide acetate market in this region.
Furthermore, huge investment in Research and development and advancement of new
techniques has caused in better care for the patients and understanding for the
medical professionals. Increase medical professionals has resulted in demand
for better standards and quality end products which will further influence the
demand in the leuprolide acetate market in the North American region.
Europe
accounted for the second largest market share for global leuprolide acetate
market. According study published by World Cancer Research fund, Europe
accounted for the largest number of individuals suffering from prone to
prostate and breast cancer influencing the European market for leuprolide acetate.
Moreover, rising number of cancer patients in the region, and steady growth in
the number of medical professionals in significantly contributes to the growth
of the European leuprolide market. Adding to this constant focus on novelty and
strict government regulations make sure high quality of products delivered to
the end users which further influence the growth of European market.
No comments:
Post a Comment